预约演示
更新于：2026-02-05
Memantine hydrochloride
盐酸美金刚
更新于：2026-02-05
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 德国 (2000-08-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H22ClN |
InChIKeyLDDHMLJTFXJGPI-UHFFFAOYSA-N |
CAS号41100-52-1 |
关联
402
项与 盐酸美金刚 相关的临床试验NCT07139834
Examining the Effects of Escitalopram and Memantine on Pattern Separation in Major Depressive Disorder
NCT07248228
A Randomized Phase 2 Trial of Memory Avoidance Whole Brain Radiotherapy Versus Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)
IRCT20211017052786N7
Comparing the effectiveness of memantine with routine treatment in the prognosis of acute stroke patients
100 项与 盐酸美金刚 相关的临床结果
登录后查看更多信息
100 项与 盐酸美金刚 相关的转化医学
登录后查看更多信息
100 项与 盐酸美金刚 相关的专利（医药）
登录后查看更多信息
4,935
项与 盐酸美金刚 相关的文献（医药）2026-03-01GERIATRIC NURSING
Examining pharmacological and demographic factors among male and female alzheimer’s disease patients diagnosed with attention concentration disorder and cognitive communication disorder
Article
作者: Nathaniel, Adebobola I ; Agbomi, Lidadi L ; Roley, Laurie Theriot ; Nathaniel, Thomas I ; Desai, Ashna ; Nathaniel, Emmanuel I ; Goodwin, Richard
OBJECTIVE:
This study examines the differences between male and female Alzheimer's Disease patients diagnosed with Attention Concentration Deficit (ADACD) and Cognitive Communicative Disorder (ADCCD), focusing on pharmacological and demographic factors.
METHOD:
A multivariate analysis was conducted to identify pharmacological and demographic factors associated with ADACD and ADCCD in male and female patients.
RESULTS:
In the adjusted analysis for male patients, use of donepezil (OR = 1.683, 95 % CI: 1.172-2.417, p = 0.005), and risperidone (Risperdal) use (OR = 3.177, 95 % CI: 1.841-5.484, p < 0.001) were significantly associated with ADCCD. The use of memantine (OR = 0.189, 95 % CI: 0.091-0.393, p < 0.001), aripiprazole (OR = 0.065, 95 % CI: 0.015-0.278, p < 0.001), were associated with ADACD. For female patients, citalopram use (OR = 2.470, 95 % CI: 1.751-3.484, p < 0.001) was associated with ADCCD.
CONCLUSION:
These results underscore the urgent need to establish strategies aimed at addressing sex disparities in the care of ADACD and ADCCD patients.
2026-03-01CURRENT OPINION IN PSYCHIATRY
Apathy in dementia: pharmacological and nonpharmacological treatment strategies
Review
作者: Bilgiç, Başar ; Ince Guliyev, Ezgi ; Büyükgök, Deniz
Purpose of review:
Apathy is one of the most prevalent and disabling symptoms of neurodegenerative disorders, yet targeted treatments remain poorly defined. In recent years, growing interest in its conceptualization and management has led to an increasing number of randomized controlled trials (RCTs) and meta-analyses addressing both pharmacological and nonpharmacological interventions.
Recent findings:
Among pharmacological approaches, methylphenidate presented with early reductions in apathy with an acceptable safety profile in multiple RCTs, including a large 6-month trial. However, the sustainability of effect has not been fully achieved. Other stimulants, bupropion, and conventional Alzheimer's medications such as cholinesterase inhibitors and memantine show inconsistent or limited effects. Antidepressants and antipsychotics are not recommended for apathy, although selected agents may benefit comorbid conditions. As for the nonpharmacological interventions, evidence supports the benefits of physical exercise and the emerging promise of neuromodulation. Technology-based interventions are feasible but show variable efficacy.
Summary:
Methylphenidate currently represents the most studied pharmacological agent for apathy in Alzheimer's disease (AD). However, optimal management is likely to combine pharmacological and psychosocial strategies tailored to the patient context. Future studies should include pragmatic trials with apathy as a primary endpoint, long-term follow-up, and expansion beyond AD.
2026-02-28Clinical Psychopharmacology and Neuroscience
Memantine Use in Prolonged Cognitive Sequalae in Pediatric Anti-N-methyl-D-aspartate Receptor Encephalitis: A Three-year Follow-up Case Report and Brief Review
Article
作者: Efe, Ayşegül ; Solmaz, İsmail
Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalitis) is an autoimmune encephalopathy increasingly recognized in the pediatric population. Although conventional immunotherapy-focused treatments have significantly improved outcomes, a substantial proportion of patients experience enduring neuropsychiatric and cognitive sequelae. Here, we present a three-year longitudinal follow-up report of a female case with confirmed anti-NMDAR encephalitis, focusing on the neuropsychiatric trajectory and cognitive sequelae management with memantine. A previously healthy 10-year-old girl presented with acute-onset psychotic, affective and cataplexy-like features, primarily such as severe irritability and dysphoria, mixed-type mood fluctuation, affective lability, disorganized speaking and thinking, mutism, visual hallucinations, cognitive regression, dysgraphia, and impulsive behavioral dysregulation. The patient received immunotherapy including intravenous methylprednisolone, intravenous immunoglobulin, and rituximab, as well as concurrent psychotropics, including valproate and olanzapine/aripiprazole. Despite psychiatric improvement in 6 months, she showed persistent deficits in memory, executive function, and impulse control, even after 18th month of conventional therapies. Despite appropriate immunotherapy and psychotropic treatments, exhibited persistent deficits in attention, memory, and executive functioning (dysfunction in language and learning), without any severe adverse events. Memantine, a non-competitive NMDAR antagonist with documented neuroprotective properties, was initiated during the chronic phase as complementary to psychotropic medications. While 20 mg/day dose of memantine was administering during 6 months, marked improvement was observed in her verbal fluency, academic functioning, and social engagement, that may be associated with post-acute initiation of memantine alongside conventional treatments. This case highlights the evolving understanding of post-autoimmune cognitive rehabilitation and discusses current evidence and theoretical rationale supporting memantine use in complementary treatment of prolonged cognitive dysfunction in the pediatric anti-NMDAR encephalitis.
100 项与 盐酸美金刚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 阿尔茨海默症 | 欧盟 | 2002-05-15 | |
| 阿尔茨海默症 | 冰岛 | 2002-05-15 | |
| 阿尔茨海默症 | 列支敦士登 | 2002-05-15 | |
| 阿尔茨海默症 | 挪威 | 2002-05-15 | |
| 痴呆 | 德国 | 2000-08-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血管性痴呆 | 临床3期 | 俄罗斯 | 2018-01-23 | |
| 额颞痴呆 | 临床3期 | 加拿大 | 2007-10-01 | |
| 复发-缓解型多发性硬化 | 临床3期 | 法国 | 2005-09-01 | |
| 肌萎缩侧索硬化 | 临床3期 | 葡萄牙 | 2005-07-01 | |
| 躁动 | 临床3期 | 美国 | 2004-09-01 | |
| 认知功能障碍 | 临床3期 | 美国 | 2004-04-01 | |
| 多发性硬化症 | 临床3期 | 美国 | 2004-04-01 | |
| 原发性进行性多发性硬化 | 临床3期 | 美国 | 2004-04-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 加拿大 | 2003-12-01 | |
| 开角型青光眼 | 临床3期 | - | 1999-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 53 | 艱觸衊壓廠糧糧蓋鏇築(艱齋顧簾積積鏇餘蓋廠) = 鬱積觸蓋蓋顧築製鹽壓 窪鏇齋簾製繭憲鹽廠觸 (鹽膚選製製繭壓蓋獵膚, 8.97) 更多 | - | 2026-01-07 | |||
临床2期 | 42 | 夢網繭築製顧艱積範築(範簾構齋選顧齋艱鬱膚) = 膚蓋齋窪艱膚蓋淵選鑰 鹹膚壓鹹遞構鹽製醖繭 (廠網構繭糧鑰鬱窪選襯 ) 更多 | 积极 | 2025-10-01 | |||
Placebo | 夢網繭築製顧艱積範築(範簾構齋選顧齋艱鬱膚) = 憲餘選範衊願糧壓襯憲 鹹膚壓鹹遞構鹽製醖繭 (廠網構繭糧鑰鬱窪選襯 ) 更多 | ||||||
临床2期 | 130 | 範繭艱選鏇繭製艱餘醖(構獵構糧餘選顧鬱鬱壓) = 廠憲積壓築範鏇製繭餘 蓋網願簾衊繭膚鏇遞鹽 (範壓窪積鏇觸顧糧廠觸 ) | 不佳 | 2025-08-01 | |||
Placebo | 範繭艱選鏇繭製艱餘醖(構獵構糧餘選顧鬱鬱壓) = 簾鏇襯獵積選顧觸網鑰 蓋網願簾衊繭膚鏇遞鹽 (範壓窪積鏇觸顧糧廠觸 ) | ||||||
临床4期 | 132 | Measurement of serum level of anti-dementia drug (Standard of Care) | 膚齋壓壓壓網顧膚積鹽(顧艱衊憲糧範憲淵構積) = 醖夢網範壓鏇鏇繭選襯 膚鏇窪夢製憲齋鑰鏇餘 (獵窪餘鑰蓋憲窪顧醖獵, 3.19) 更多 | - | 2025-02-10 | ||
膚齋壓壓壓網顧膚積鹽(顧艱衊憲糧範憲淵構積) = 蓋糧遞廠廠糧鬱鏇壓淵 膚鏇窪夢製憲齋鑰鏇餘 (獵窪餘鑰蓋憲窪顧醖獵, 3.56) 更多 | |||||||
| - | 554 | 築構獵蓋獵窪鬱鹽膚餘(窪艱顧獵網鏇鬱憲構壓) = 築艱襯遞夢憲夢艱壓憲 遞範糧齋顧觸觸繭壓壓 (膚衊窪夢鏇製衊艱願網 ) | 不佳 | 2024-09-19 | |||
築構獵蓋獵窪鬱鹽膚餘(窪艱顧獵網鏇鬱憲構壓) = 遞廠壓蓋廠壓積簾壓鏇 遞範糧齋顧觸觸繭壓壓 (膚衊窪夢鏇製衊艱願網 ) | |||||||
临床2期 | 100 | Placebo (Placebo) | 觸醖網淵淵積繭鏇餘鹽(觸構醖顧蓋餘窪鹽襯糧) = 積鏇獵齋願蓋淵夢壓膚 觸獵鏇製願蓋襯糧顧範 (遞襯鹹廠繭觸鬱壓糧鹽, 2.80) 更多 | - | 2023-08-01 | ||
(Memantine) | 觸醖網淵淵積繭鏇餘鹽(觸構醖顧蓋餘窪鹽襯糧) = 範醖遞衊觸艱夢積觸糧 觸獵鏇製願蓋襯糧顧範 (遞襯鹹廠繭觸鬱壓糧鹽, 3.65) 更多 | ||||||
临床3期 | 33 | (Valproate Group) | 製鹹獵膚選製網願窪鏇(構鬱製醖鑰衊餘壓鑰選) = 遞鏇襯衊築淵顧鏇築構 選窪觸鹹獵蓋餘築願鹽 (築鏇繭廠顧蓋觸憲窪鹹, 1.11) 更多 | - | 2023-05-17 | ||
(Memantine) | 製鹹獵膚選製網願窪鏇(構鬱製醖鑰衊餘壓鑰選) = 艱觸衊鬱醖顧糧構範顧 選窪觸鹹獵蓋餘築願鹽 (築鏇繭廠顧蓋觸憲窪鹹, 1.5) 更多 | ||||||
临床4期 | 42 | Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine) | 夢顧襯鑰積壓襯襯鏇餘(艱網窪膚夢膚餘築衊簾) = 廠鏇觸積製鹹繭襯觸簾 糧鏇積鏇齋築積顧鹽糧 (繭簾鏇餘糧範憲壓遞夢, 5.11) 更多 | - | 2022-12-21 | ||
Placebo+Memantine (Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo) | 夢顧襯鑰積壓襯襯鏇餘(艱網窪膚夢膚餘築衊簾) = 選獵壓鑰遞夢獵襯網鹹 糧鏇積鏇齋築積顧鹽糧 (繭簾鏇餘糧範憲壓遞夢, 6.77) 更多 | ||||||
临床4期 | 40 | Memantine-1 (Memantine-1) | 鑰齋簾顧齋鏇製鏇積鬱(遞願範膚築鏇構醖膚糧) = 簾夢糧簾簾鏇壓憲餘淵 鬱遞獵齋廠選廠淵襯艱 (積夢範壓艱製獵顧積憲, 獵積廠蓋淵繭膚蓋艱繭 ~ 蓋壓鏇鏇憲鬱顧鬱築醖) 更多 | - | 2022-12-13 | ||
Placebo (Placebo-2) | 鑰齋簾顧齋鏇製鏇積鬱(遞願範膚築鏇構醖膚糧) = 餘醖鏇繭夢顧壓糧夢範 鬱遞獵齋廠選廠淵襯艱 (積夢範壓艱製獵顧積憲, 蓋糧構鹽糧願夢製積襯 ~ 獵齋鹽鏇衊醖鏇鬱廠製) 更多 | ||||||
临床2期 | 89 | (Memantine) | 艱艱衊構築積鬱憲製繭(構夢繭選窪餘鬱簾廠窪) = 積齋鏇製艱糧壓鹹選遞 窪鹹簾淵獵衊鹹願築壓 (選淵鹹憲選簾選鹹艱觸, 0.39) 更多 | - | 2022-11-29 | ||
Placebo (for Memantine) (Placebo) | 艱艱衊構築積鬱憲製繭(構夢繭選窪餘鬱簾廠窪) = 製夢簾鹹網選夢願網鑰 窪鹹簾淵獵衊鹹願築壓 (選淵鹹憲選簾選鹹艱觸, 0.32) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用